NCT04213222

Radiomics Assess of Bevacizumab Plus Chemo in Colorectal Cancer Liver Metastases

A Radiomics Approach to Predict the Effect of Bevacizumab Plus Chemotherapy in Patients With Liver Metastases of Colorectal Cancer: A Prospective Multi-Centers Trial

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 300 (estimated)
• Sponsor: Peking University People's Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Colorectal carcinoma with liver metastasis is one of the major problems bothering physicians worldwide. Bevacizumab combined with chemotherapy is the standard treatment recommended by several guidelines. Despite the high cost, a certain portion of patients couldn't benefit from this therapy. This study is aiming to find out the specific type of patients who would respond to bevacizumab by Radiomics approach, and evaluate the prediction value of this imaging model with clinical and genetic factors.

Conditions

• Colon Cancer
• Rectal Cancer
• Liver Metastases

Interventions

Type	Name	Description
DRUG	Bevacizumab	bevacizumab combined with chemotherapy

Timeline

• Start date: 2020-10-01
• Primary completion: 2022-06-01
• Completion: 2023-12-01
• First posted: 2019-12-30
• Last updated: 2020-08-11

Locations

1 site across 1 country: China

Regulatory

• FDA-regulated drug study